With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...

Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...

This piece is part of a series that dives deeper into the most prevalent themes of this year’s iteration of our flagship research piece, Charting Disruption. Click to read.

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

Neurocrine Biosciences Inc. has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and ...

The discovery and development of drugs in pharmacological research – including the risk assessment of active substances in ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

VALID, a Techbio startup dedicated to reshaping drug discovery with complex human induced pluripotent stem cell (iPSC) co-culture models that deliver increased predictive validity, has partnered with ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

Immunopathologies encompass a range of conditions known for their defined pathophysiology but lack safe and effective treatment options. These diseases ...